Log in to search using one of your social media accounts:

 

Roche ’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis

Roche announced today that the European Commission (EC) has granted marketing authorisation for OCREVUS ® (ocrelizumab) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory ac tivity.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

No abstract available
Source: Neurology Today - Category: Neurology Tags: Features Source Type: research
CONCLUSIONS: Our results show that, among patients with multiple sclerosis, those who were older, with higher perceived disability and higher depression symptoms have more and more severe work-related difficulties. The Multiple Sclerosis Questionnaire for Job Difficulties can be fruitfully exploited to plan tailored actions to limit the likelihood of near-future job loss in persons of working age with multiple sclerosis. Implications for rehabilitation Difficulties with work are common among people with multiple sclerosis and are usually addressed in terms of unemployment or job loss. The Multiple Sclerosis Questionnaire f...
Source: Disability and Rehabilitation - Category: Rehabilitation Authors: Tags: Disabil Rehabil Source Type: research
CONCLUSION: Patient characteristics differ between private and academic centers. Over 55% of patients achieved NEDA-3 during fingolimod treatment at both center types. PMID: 29648900 [PubMed - as supplied by publisher]
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Authors: Narayan RN, Forsthuber T, Stüve O Abstract INTRODUCTION: While substantial progress has been made in the past three decades in treating relapsing forms of multiple sclerosis, the identification of effective therapies for progressive forms of multiple sclerosis (MS) has remained mostly elusive, and remains a priority and challenge for the global MS community. Although axonal degeneration in a setting of demyelination, failure of remyelination, neuronal death, axonal energy failure have been implicated in this disease process, a more complete understanding of the mechanisms involved in the pathogenesis ...
Source: Expert Opinion on Emerging Drugs - Category: Drugs & Pharmacology Tags: Expert Opin Emerg Drugs Source Type: research
In the early phases of relapsing-remitting multiple sclerosis (RR-MS), a clear correlation between brain lesion load and clinical disability is often lacking, originating the so-called clinico-radiological par...
Source: Journal of Neuroinflammation - Category: Neurology Authors: Tags: Research Source Type: research
Publication date: May 2018 Source:The Lancet Neurology, Volume 17, Issue 5 Author(s): Eugene O Major, Tarek A Yousry, David B Clifford Progressive multifocal leukoencephalopathy (PML) is a rare, devastating demyelinating disease of the CNS caused by the JC virus (JCV) that occurs in patients with compromised immune systems. Detection of PML in systemically immunocompetent patients with multiple sclerosis treated with natalizumab points to a role for this drug in the pathophysiology of PML. Emerging knowledge of the cellular and molecular biology of JCV infection and the pathogenesis of PML—including interplay of thi...
Source: The Lancet Neurology - Category: Neurology Source Type: research
Conclusion OCT detected GCC changes in EAE may resemble what is observed in MS-related acute ON: an initial phase of swelling (indicative of inflammatory edema) followed by a decrease in thickness over time (representative of neuro-axonal degeneration). In line with OCT findings, DTI of the visual pathway identifies EAE induced pathology (decreased AD, and increased RD). Immunofluorescence analysis provides support for inflammatory pathology and axonal degeneration. OCT together with DTI can detect retinal and optic nerve damage and elucidate to the temporal sequence of neurodegeneration in this rodent model of MS in vivo.
Source: NeuroImage - Category: Neuroscience Source Type: research
We examined whether hopping to a metronome beat has the potential to detect anticipatory motor control deficits among people with mild MS (Expanded Disability Status Scale  ≤ 3.5).
Source: Clinical Biomechanics - Category: Orthopaedics Authors: Source Type: research
(Bentham Science Publishers) Neurocognitive impairment is frequently encountered in multiple sclerosis patients affecting between 40-65 percent of these individuals, irrespective of disease duration, severity of physical disability, and at both the earlier and later disease stages, with a tendency to worsen over time.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
ettl UK Abstract MAIN PROBLEM: Treatment options for multiple sclerosis (MS) have enlarged tremendously over the last years. Nonetheless, lots of patients look for alternative treatment options. The use of complementary and alternative medicine (CAM) is widespread in MS, however, its scientific investigation is limited so far. The aim of the study is to analyse clinical and demographical differences of MS patients in dependency of their CAM utilization as coping strategy. METHODS: A total of 254 patients with a clinically definite MS were examined in a semistructured interview. Additional standardized questio...
Source: CNS Neuroscience and Therapeutics - Category: Neuroscience Authors: Tags: CNS Neurosci Ther Source Type: research
More News: Disability | Marketing | Multiple Sclerosis | Pharmaceuticals